HCM – hutchmed (china) limited - american depositary shares (US:NASDAQ)
Stock Stats
News
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda [Yahoo! Finance]
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
Form 6-K HUTCHMED (China) Ltd For: Nov 06
Form 6-K HUTCHMED (China) Ltd For: Oct 31
Form 6-K HUTCHMED (China) Ltd For: Oct 21
Form 6-K HUTCHMED (China) Ltd For: Oct 16
Form 6-K HUTCHMED (China) Ltd For: Sep 24
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.